Pre-infection HDL-cholesterol levels and mortality among elderly patients infected with SARS-CoV-2

Atherosclerosis. 2022 Jan:341:13-19. doi: 10.1016/j.atherosclerosis.2021.12.009. Epub 2021 Dec 22.

Abstract

Background and aims: Low HDL-cholesterol (HDLc) concentration is associated with a greater risk of infection-related mortality. We wanted to evaluate the relationship between pre-infection HDLc levels and mortality among older patients infected with SARS-Cov-2.

Methods: This is a population-based, cohort study, comprising all individuals residing in Madrid (Spain) born before 1 January 1945, and alive on 31 December 2019. Demographic, clinical, and analytical data were obtained from the primary care electronic clinical records. Confirmed SARS-CoV-2 infection was defined as a positive result in the RT-qPCR or in the antigen test. A death from COVID-19 was defined as that registered in the hospital chart, or as any death occurring in the 15 days following a confirmed SARS-CoV-2 infection. Data on infection, hospitalization, or death due to SAR-CoV-2 were collected from 1 March 2020 through 31 December 2020.

Results: Of the 593,342 individuals comprising the cohort, 36,966 had a SARS-CoV-2 infection during 2020, and at least one HDLc measurement in the previous five years. Among them, 9689 (26.2%) died from COVID-19. After adjustment for age and sex, the relative risk (95% confidence interval) of COVID-19 death across increasing quintiles of HDLc was 1.000, 0.896 (0.855-0.940), 0.816 (0.776-0.860), 0.758 (0.719-0.799), and 0.747 (0.708-0.787). The association was maintained after further adjustment for comorbidities, statin treatment and markers of malnutrition. While in females this association was linear, in males it showed a U-shaped curve.

Conclusions: In older subjects, a higher HDLc measured before SARS-CoV-2 infection was associated with a lower risk of death.

Keywords: COVID-19; HDL-Cholesterol; Infection; Lipoproteins; SARS-CoV-2 infection.

MeSH terms

  • Aged
  • COVID-19*
  • Cholesterol, HDL
  • Cohort Studies
  • Female
  • Humans
  • Male
  • SARS-CoV-2*
  • Treatment Outcome

Substances

  • Cholesterol, HDL